drugset / Trial / NCT06559553
"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
NaSingle-groupOpen-labelTreatment
Summary
evaluate the efficacy and safety of "Selinexor+pegaspargase+dexamethasone" in early stage NK/ T-cell lymphoma
Timeline
- Start
- 2024-09-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Pegaspargase | Protein / enzyme biologic | — | Oral |
| Subject | Selinexor | Other / unclassified | — | Oral |